Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
- 27 January 2009
- journal article
- review article
- Published by Wiley in Acta Psychiatrica Scandinavica
- Vol. 119 (3), 171-179
- https://doi.org/10.1111/j.1600-0447.2008.01334.x
Abstract
To provide an overview for practicing clinicians on the pharmacological basis of cardiometabolic risk induced by antipsychotic drugs in patients with serious mental illness, to propose hypotheses to explain these risks and to give tips for managing cardiometabolic risk during antipsychotic treatment. A MEDLINE search using terms for atypical antipsychotics (including individual drug names), metabolic, cardiovascular, weight gain and insulin resistance, cross-referenced with schizophrenia was performed on articles published between 1990 and May 2008. Strong evidence exists for significant cardiometabolic risk differences among several antipsychotic agents. Histamine H1 and serotonin 5HT2C antagonism are associated with risk of weight gain, but receptor targets for dyslipidemia and insulin resistance have not yet been identified. Convincing data indicate that hypertriglyceridemia and insulin resistance may occur in the absence of weight gain with certain antipsychotics. Although lifestyle and genetics may contribute independent risks of cardiometabolic dysfunction in schizophrenia and other serious mental illness, antipsychotic treatment also represents an important contributor to risk of cardiometabolic dysfunction, particularly for certain drugs and for vulnerable patients. Mental health professionals must learn to recognize the clinical signposts indicating antipsychotic-related cardiometabolic problems to forestall progression to type II diabetes, cardiovascular events and premature death.Keywords
This publication has 46 references indexed in Scilit:
- Atypical antipsychotic‐induced diabetes mellitus: an update on epidemiology and postulated mechanismsInternal Medicine Journal, 2008
- Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1Schizophrenia Research, 2008
- Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjectsSchizophrenia Research, 2008
- A systematic review of mortality in schizophrenia - Is the differential mortality gap worsening over time?Archives of General Psychiatry, 2007
- Body Mass Indexes and Lipid Profiles in Hospitalized Children and Adolescents Exposed to Atypical AntipsychoticsJournal of Child and Adolescent Psychopharmacology, 2007
- Antipsychotic drug-induced weight gain mediated by histamine H1receptor-linked activation of hypothalamic AMP-kinaseProceedings of the National Academy of Sciences of the United States of America, 2007
- Second-Generation Antipsychotic Exposure and Metabolic-Related Disorders in Patients With SchizophreniaJournal of Clinical Psychopharmacology, 2007
- Diabetes Risk Associated with Use of Olanzapine, Quetiapine, and Risperidone in Veterans Health Administration Patients with SchizophreniaAmerican Journal of Epidemiology, 2006
- Prevalence of Overweight and Obesity in the United States, 1999-2004Published by American Medical Association (AMA) ,2006
- Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptorsNature, 1995